Nonclinical safety of mavrilimumab, an anti-GMCSF receptor alpha monoclonal antibody, in cynomolgus monkeys: Relevance for human safety

Toxicology and Applied Pharmacology

Volumn 279, Issue 2, 2014, Pages 230-239

  Ryan, Patricia C ^a   Sleeman, Matthew A ^a   Rebelatto, Marlon ^a   Wang, Bing ^a   Lu, Hong ^a   Chen, Xiaomin ^b   Wu, Chi Yuan ^a   Hinrichs, Mary Jane ^a   Roskos, Lorin ^a   Towers, Heidi ^a   McKeever, Kathleen ^a   Dixit, Rakesh ^a  

^a MEDIMMUNE   (United States)

^b NOVARTIS PHARMA AG   (Switzerland)

Author keywords

Alveolar macrophage; Biologics; GMCSF receptor; Mavrilimumab; Rheumatoid arthritis; Safety assessment

Indexed keywords

CHOLESTEROL; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; MAVRILIMUMAB;

ANIMAL EXPERIMENT; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DRUG CLEARANCE; DRUG ELIMINATION; DRUG SAFETY; FEMALE; IMMUNOGENICITY; LUNG ALVEOLUS MACROPHAGE; LUNG GRANULOMATOSIS; LUNG TOXICITY; MACACA FASCICULARIS; MALE; MAXIMUM PLASMA CONCENTRATION; NONHUMAN; TIME TO MAXIMUM PLASMA CONCENTRATION; TREATMENT DURATION;

ALVEOLAR MACROPHAGE; BIOLOGICS; GMCSF RECEPTOR; MAVRILIMUMAB; RHEUMATOID ARTHRITIS; SAFETY ASSESSMENT;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FOAM CELLS; HUMANS; INJECTIONS, INTRAVENOUS; INJECTIONS, SUBCUTANEOUS; LUNG; MACACA FASCICULARIS; MACROPHAGES, ALVEOLAR; MALE; MODELS, ANIMAL; NO-OBSERVED-ADVERSE-EFFECT LEVEL; RECEPTORS, GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; RISK ASSESSMENT; TOXICITY TESTS;

EID: 84904252983     PISSN: 0041008X     EISSN: 10960333     Source Type: Journal    
DOI: 10.1016/j.taap.2014.06.002     Document Type: Article

References (27)

1. Atochina-Vasserman E.N., Winkler C., Abramova H., Schaumann F., Krug N., Gow A.J., et al. Segmental allergen challenge alters multimeric structure and function of surfactant protein D in humans. Am. J. Respir. Crit. Care Med. 2011, 183(7):856-864.
2. Burmester G.R., Feist E., Sleeman M.A., Wang B., White B., Magrini F. Mavrilimumab, a human monoclonal antibody targeting GM-CSF receptor-α, in subjects with rheumatoid arthritis: a randomised, double-blind, placebo-controlled, phase I, first-in-human study. Ann. Rheum. Dis. 2011, 70(9):1542-1549.
3. Burmester G.R., Weinblatt M.E., McInnes I.B., Porter D., Barbarash O., Vatutin M., Szombati I., Esfandiari E., Sleeman M.A., Kane C.D., Cavet G., Wang B., Godwood A., Magrini F for the EARTH Study Group Efficacy and safety of mavrilimumab in subjects with rheumatoid arthritis. Ann. Rheum. Dis. 2013, 72(9):1445-1452.
4. Carey B., Trapnell B.C. The molecular basis of pulmonary alveolar proteinosis. Clin. Immunol. 2010, 135(2):223-235.
5. Courtice F.C. Lymph Flow in the Lungs. Br. Med. Bull. 1963, 19(1):76.
6. Dranoff G., Crawford A.D., Sadelain M., et al. Involvement of granulocyte-macrophage colony stimulating factor in pulmonary homeostasis. Science 1994, 264:713-716.
7. Drevon-Gaillot E., Perron-Lepage M., Clement C., Burnett R. A review of background findings in cynomolgus monkeys (Macaca fascicularis) from three different geographical origins. Exp. Toxicol. Pathol. 2006, 58:77-88.
8. Forbes B., O'Lone R., Pribul Allen P., et al. Challenges for inhaled drug discovery and development: induced alveolar macrophage responses. Adv. Drug Deliv. Rev 2014, 10.1016/j.addr.2014.02.001.
9. Hant F.N., Ludwicka-Bradley A., Wang H.J., Li N., Elashoff R., Tashkin D.P., Silver R.M. Scleroderma Lung Study Research Group. Surfactant protein D and KL-6 as serum biomarkers of interstitial lung disease in patients with scleroderma. J. Rheumatol. 2009, 36(4):773-780.
10. Imai T., Takase M., Takeda S., Kougo T. Serum KL-6 levels in pediatric patients: reference values for children and levels in pneumonia, asthma, and measles patients. Pediatr. Pulmonol. 2002, 33(2):135-141.
11. Kondo T., Hattori N., Ishikawa N., Murai H., Haruta Y., Hirohashi N., et al. KL-6 concentration in pulmonary epithelial lining fluid is a useful prognostic indicator in patients with acute respiratory distress syndrome. Respir. Res. 2011, 12:32.
12. Kucejko W., Chyczewska E., Naumnik W., Ossolińska M. Concentration of surfactant protein D, Clara cell protein CC-16 and IL-10 in bronchoalveolar lavage (BAL) in patients with sarcoidosis, hypersensivity pneumonitis and idiopathic pulmonary fibrosis. Folia Histochem. Cytobiol. 2009, 47(2):225-230.
13. Lewis D.J., Williams T.C., Beck S.L. Foamy macrophage responses in the rat lung following exposure to inhaled pharmaceuticals: a simple, pragmatic approach for inhaled drug development. J. Appl. Toxicol. 2014, 34:319-331.
14. Minter R.R., Cohen E.S., Wang B., Liang M., Vainshtein I., Rees G., Eghobamien L., Harrison P., Sims D.A., Matthews C., Wilkinson T., Monk P., Drinkwater C., Fabri L., Nash A., McCourt M., Jermutus L., Roskos L., Anderson I.K., Sleeman M.A. Protein engineering and preclinical development of a GM-CSF receptor antibody for the treatment of rheumatoid arthritis. Br. J. Pharmacol. 2012, 168(1):200-211.
15. Ohshimo S., Bonella F., Grammann N., Starke K., Cui A., Bauer P.C., et al. Serum KL-6 as a novel disease marker in adolescent and adult cystic fibrosis. Sarcoidosis Vasc. Diffuse Lung Dis. 2009, 26(1):47-53.
16. Olesen H.V., Holmskov U., Schiøtz P.O., Sørensen G.L. Serum-surfactant SP-D correlates inversely to lung function in cystic fibrosis. J. Cyst. Fibros. 2010, 9(4):257-262.
17. Reed J.A., Whitsett J.A. Granulocyte-macrophage colony-stimulating factor and pulmonary surfactant homeostasis. Proc. Assoc. Am. Physicians 1998, 110(4):321-332. (Jul-Aug).
18. Reed J.A., Ikegami M., Robb L.C., Begley G., Ross G., Whitsett J.A. Distinct changes in pulmonary surfactant homeostasis in common beta-chain and GM-CSF-deficient mice. Am. J. Physiol. Lung Cell. Mol. Physiol. 2000, 278:L1164-L1171.
19. Robb L., Drinkwater C.C., Metcalf D., Li R., Kontgen F., Nicola N.A., Begley C.G. Hematopoietic and lung abnormalities in mice with a null mutation of the common beta subunit of the receptors for granulocyte-macrophage colony-stimulating factor and interleukins 3 and 5. Proc. Natl. Acad. Sci. U. S. A. 1995, 92:9565-9569.
20. Sakagami T., Beck D., Uchida K., Suzuki T., Carey B.C., Nakata K., et al. Patient-derived granulocyte/macrophage colony-stimulating factor autoantibodies reproduce pulmonary alveolar proteinosis in nonhuman primates. Am. J. Respir. Crit. Care Med. 2010, 182(1):49-61.
21. Stanley E., Lieschke G.J., Grail D., et al. Granulocyte/macrophage colony-stimulating factor deficient mice show no major perturbation of hematopoiesis but develop a characteristic pulmonary pathology. Proc. Natl. Acad. Sci. U. S. A. 1994, 91:5592-5596.
22. Trapnell B.C., Whitsett J.A. GM-CSF regulates pulmonary surfactant homeostasis and alveolar macrophage-mediated innate host defense. Annu. Rev. Physiol. 2002, 64:775-802.
23. Uchida K., Nakata K., Suzuki T., et al. Granulocyte/macrophage-colony-stimulating factor autoantibodies and myeloid cell immune functions in healthy subjects. Blood 2009, 113(11):2547-2556.
24. Wang D., Zhang S., Zhao H., Men A.Y., Parivar K. Fixed dosing versus body size-based dosing of monoclonal antibodies in adult clinical trials. J. Clin. Pharm. 2009, 49:1012-1024.
25. Wang B., Lau Y.Y., Liang M., Vainshtein I., Zusmanovich M., Lu H., Magrini F., Sleeman M., Roskos L. Mechanistic modeling of antigen sink effect for mavrilimumab following intravenous administration in patients with rheumatoid arthritis. J. Clin. Pharm. 2012, 52(8):1150-1161.
26. Ware L.B., Koyama T., Billheimer D.D., Wu W., Bernard G.R., Thompson B.T., et al. Prognostic and pathogenetic value of combining clinical and biochemical indices in patients with acute lung injury. Chest 2010, 137(2):288-296.
27. Yoshida M., Ikegami M., Reed J.A., Chroneos Z.C., Whitsett J.A. GM-CSF regulates protein and lipid catabolism by alveolar macrophages. Am. J. Physiol. Lung Cell. Mol. Physiol. 2001, 280:L379-L386.